Journal of Medicinal Chemistry · 2016 · 69 citations · 26 references
Life SciencesMedicinal ChemistryMolecular BiologyChromatin BiologyDrug DesignDrug DiscoveryChromatinChromatin ArchitectureEnzyme InhibitionHistone ProteinsLigand BindingProtein-ligand BindingBromodomain InhibitionBromodomain Protein TargetingBromodomain ProteinsChromatin DomainsCompound IdentificationDisplacementLigand ScreeningSelectivity
Bromodomain containing proteins PB1, SMARCA4, and SMARCA2 are important components of SWI/SNF chromatin remodeling complexes. We identified bromodomain inhibitors that target these proteins and display unusual binding modes involving water displacement from the KAc binding site. The best compound binds the fifth bromodomain of PB1 with a KD of 124 nM, SMARCA2B and SMARCA4 with KD values of 262 and 417 nM, respectively, and displays excellent selectivity over bromodomains other than PB1, SMARCA2, and SMARCA4.
26
BET Bromodomain Inhibition as a Therapeutic Strategy to Target c-Myc
Jake Delmore, Ghayas C. Issa, Madeleine E. Lemieux et al. · Cell · 2011 · 2.8K citations · Full text
Histone Recognition and Large-Scale Structural Analysis of the Human Bromodomain Family
P. Filippakopoulos, S. Picaud, Maria Mangos et al. · Cell · 2012 · 1.8K citations · Full text
Suppression of inflammation by a synthetic histone mimic
Edwige Nicodème, Kate L. Jeffrey, Uwe Schaefer et al. · Nature · 2010 · 1.6K citations · Full text
Inhibition of BET recruitment to chromatin as an effective treatment for MLL-fusion leukaemia
Mark A. Dawson, Rab K. Prinjha, Antje Dittmann et al. · Nature · 2011 · 1.5K citations · Full text